Clinical Trial Update: Expanded Access to Elezanumab

View source ↗

Summary

This document provides an expanded access update for Elezanumab. It concerns patients with acute spinal cord injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Elezanumab (elezanumab)

Snippet

Sponsor: AbbVie | Conditions: Acute Spinal Cord Injury (SCI) | Status: AVAILABLE